{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"9"}]}],"title":"Anemia (Baseline G0 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"21"}]}],"title":"Anemia (Baseline G1 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"14"}]}],"title":"Anemia (Baseline G2 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Anemia (Baseline G3 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"53"}]}],"title":"Lymphocytes count decreased (Baseline G0 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}]}],"title":"Lymphocytes count decreased (Baseline G1 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"15"}]}],"title":"Lymphocytes count decreased (Baseline G2 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"}]}],"title":"Lymphocytes count decreased (Baseline G3 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"108"}]}],"title":"Neutrophils count decreased (Baseline G0 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Neutrophils count decreased (Baseline G1 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Neutrophils count decreased (Baseline G2 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"61"}]}],"title":"Platelets count decreased (Baseline G0 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"}]}],"title":"Platelets count decreased (Baseline G1 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"35"}]}],"title":"WBC decreased (Baseline G0 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"}]}],"title":"WBC decreased (Baseline G1 to post-baseline G3-4)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"WBC decreased (Baseline G2 to post-baseline G3-4)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"428"},{"groupId":"OG001","value":"434"}],"units":"Participants"}],"description":"Following hematology parameters were assessed: hemoglobin decreased (anemia), hemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cell (WBC) decreased. Laboratory abnormalities were graded as per NCI- CTCAE v 4.03 where, grade(G) 0= non-missing lab value that does not meet either of G1 through 4 criteria, G1=mild, G2=moderate, G3=severe, G4=life-threatening consequences and G5=death. Baseline was defined as last assessment prior to first dose of study treatment. Number of participants with a baseline grade of 0 to 4 which shifted to G3-4 post-baseline are reported in this outcome measure. Only non-zero categories for any reporting arm are reported.","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set included all participants who received at least one dose of study drug. Here \"Number of Participants Analyzed\" signifies number of participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From start of study treatment until 90 days after last dose of study treatment (maximum up to approximately 92 months)","title":"Number of Participants According to Grade Shift in Hematology Parameters","type":"SECONDARY","unitOfMeasure":"Participants"}